APA (7th ed.) Citation

S, B., J, L., FS, H., F, S., EHW, K., GK, S., . . . RD, C. (2023). A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in oncology, 12, 975642. https://doi.org/10.3389/fonc.2022.975642

Chicago Style (17th ed.) Citation

S, Bauer, et al. "A Phase Ib Trial of Combined PKC and MEK Inhibition with Sotrastaurin and Binimetinib in Patients with Metastatic Uveal Melanoma." Frontiers in Oncology 12 (2023): 975642. https://doi.org/10.3389/fonc.2022.975642.

MLA (9th ed.) Citation

S, Bauer, et al. "A Phase Ib Trial of Combined PKC and MEK Inhibition with Sotrastaurin and Binimetinib in Patients with Metastatic Uveal Melanoma." Frontiers in Oncology, vol. 12, 2023, p. 975642, https://doi.org/10.3389/fonc.2022.975642.